|
Selected(0)Clear
Items/Page: Sort: |
| Research and development of hepatitis b drugs: an analysis based on technology flows measured by patent citations Book chapter
出自: Innovation Value Chain Of Chinese Pharmaceuticals:United States-China Intellectual Property Institute Inc., 2017, 页码:159-186
Authors: Huang, CJ; Lin, HH; Wan, JB; He, CW ; Hu, YJ
  Favorite | | Submit date：2022/08/07 |
| Monitoring drug research on clinical neurology in China: An analysis of institutional leaders and community themes Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:53-72
Authors: Ka Weng Si Tou; Jianbo Wan; Marvin S.H. Mak; Yifan Han; Yuanjia Hu
Favorite | | Submit date：2019/01/14
Neurological Drugs Thematic Analysis Greater China Publications Research Collaboration Networks |
| China’s landscape of discovering miRNAs in cancer Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:73-90
Authors: Hengwa Kuok; Xiangjun Kong; Yuanjia Hu; Yitao Wang
Favorite | | Submit date：2019/01/14 |
| Global landscape of research and development on antibiotics Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:91-114
Authors: Xiangjun Kong; Hong Lu; Qianru Zhang; Huali Zuo; Yuanjia Hu; et al.
Favorite | | Submit date：2019/01/14 |
| Collaboration networks for R&D of monoclonal antibodies: An analysis based on pipeline projects Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:135-158
Authors: Tianhong Yin; Xiangjun Kong; Yitao Wang; Xin Chen; Yuanjia Hu; et al.
Favorite | | Submit date：2019/01/14
Monoclonal Antibodies Research And Development Network Analysis Institutional Collaboration Network Country-based Collaboration Network |
| An analysis of technology flows of antidepressants based on patent citation network Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:187-208
Authors: Siqi Tian; Hui Heng Lin; Marvin S.H. Mak; Yifan Han; Yuanjia Hu
Favorite | | Submit date：2019/01/14 |
| Entry inhibitors for AIDS therapy: A review of research and development projects Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:115-134
Authors: Xiangjun Kong; Hongyu Liang; Qingwen Yuan; Yuanjia Hu
Favorite | | Submit date：2019/01/14 |
| Pharmaceutical patent valuation based on empirical models Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:209-220
Authors: Jingyun Ni; Rong Shao; Carolina Oi Lam Ung; Yitao Wang; Yuanjia Hu; et al.
Favorite | | Submit date：2019/01/14
Pharmaceutical Patents Patent Value Valuation Echnological Factors Commercial Factors Legal Factors |
| Pharmaceutical innovation network: Global patterns and the role of China Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:259-281
Authors: Pengpeng Li; Huiheng Lin; Yuanjia Hu
Favorite | | Submit date：2019/01/15
Pharmaceutical Innovation Drug Patents Network Analysis |
| Changing pharmaceutical registration rules in China: Latest update and potential impacts Book chapter
出自: Innovation Value Chain of Chinese Pharmaceuticals, Whitestone, New York:United States-China Intellectual Property Institute Inc., 2017, 页码:241-258
Authors: Miao Wan; Junrui Zhao; Bingyu Zhang; Dongning Yao; Yuanjia Hu
Favorite | | Submit date：2019/01/15 |
